Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

47.80 -1.03 (-2.11%)
Streaming Delayed Price Updated: 1:12 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
From Komodo Health
Via Business Wire
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MarketBeat Week in Review – 6/26 - 6/30
Markets headed into a holiday week cheering a lower-than-expected key inflation reading, but investors should expect volatility in a short trading week. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
MoonLake Immunotherapeutics Makes a Moonshot on Trials
Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results. 
Via MarketBeat
Exposures Product Safety
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
BioMedNewsBreaks – MoonLake Immunotherapeutics’ (NASDAQ: MLTX) Shares See Significant Increase Based on Success of Phase 2 Trial
Via Investor Brand Network
MoonLake Immunotherapeutics (NASDAQ: MLTX) Announces Breakthrough Results for Sonelokimab in Phase 2 Trial
MoonLake Immunotherapeutics (NASDAQ: MLTX) has made significant strides with the successful outcome of their Phase 2 MIRA trial for sonelokimab, 
Via Spotlight Growth
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.